HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Stefan Zeuzem Selected Research

Interferon alpha-2 (Roferon-A)

9/2012Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection.
1/2009Optimal therapy in genotype 1 patients.
8/2008Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.
1/2005Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial.
2/2004Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data.
7/2003Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.
1/2003Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
12/2002Mycophenolate mofetil in combination with recombinant interferon alfa-2a in interferon-nonresponder patients with chronic hepatitis C.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Stefan Zeuzem Research Topics

Disease

205Infections
02/2022 - 04/2002
169Chronic Hepatitis C
01/2022 - 10/2002
101Fibrosis (Cirrhosis)
04/2022 - 07/2003
77Hepatitis C
04/2022 - 04/2002
46Liver Cirrhosis (Hepatic Cirrhosis)
07/2022 - 01/2008
39Liver Diseases (Liver Disease)
01/2022 - 09/2006
38Hepatocellular Carcinoma (Hepatoma)
12/2021 - 11/2007
37Neoplasms (Cancer)
07/2021 - 02/2002
33Chronic Hepatitis B
01/2022 - 04/2002
16Virus Diseases (Viral Diseases)
01/2020 - 10/2006
13Hepatitis B
04/2022 - 06/2003
12Colorectal Neoplasms (Colorectal Cancer)
03/2022 - 02/2002
12Inflammation (Inflammations)
10/2020 - 10/2006
12Viremia
05/2014 - 04/2002
11Fatigue
01/2022 - 01/2003
11End Stage Liver Disease
05/2020 - 09/2012
11Anemia
03/2016 - 04/2009
10Body Weight (Weight, Body)
05/2014 - 06/2004
9Hepatitis D
01/2021 - 01/2011
9Coinfection
01/2020 - 11/2008
8Pathologic Constriction (Stenosis)
08/2022 - 03/2013
7Hemorrhage
01/2022 - 01/2013
7Acute-On-Chronic Liver Failure
12/2021 - 08/2018
7Liver Failure
01/2018 - 11/2007
6Ascites
10/2022 - 09/2012
6Hepatitis
01/2021 - 11/2004
6Insulin Resistance
08/2020 - 12/2010
6Exanthema (Rash)
03/2016 - 04/2009
5Neoplasm Metastasis (Metastasis)
01/2019 - 12/2008
4Cholangiocarcinoma
04/2022 - 02/2017
4Chronic Renal Insufficiency
01/2022 - 11/2018

Drug/Important Bio-Agent (IBA)

137Ribavirin (Virazole)FDA LinkGeneric
01/2021 - 12/2002
124Antiviral Agents (Antivirals)IBA
02/2022 - 04/2002
97InterferonsIBA
02/2022 - 10/2002
50RNA (Ribonucleic Acid)IBA
01/2021 - 10/2002
33Interferon-alpha (Interferon Alfa)IBA
01/2021 - 04/2002
32SofosbuvirIBA
01/2021 - 05/2014
29Protease Inhibitors (Protease Inhibitor)IBA
12/2018 - 09/2007
29telaprevirIBA
03/2016 - 10/2006
22peginterferon alfa-2a (Pegasys)FDA Link
01/2019 - 10/2002
21Hepatitis B e AntigensIBA
01/2022 - 01/2005
21Proteins (Proteins, Gene)FDA Link
07/2021 - 08/2004
19Biomarkers (Surrogate Marker)IBA
04/2022 - 01/2010
14Pharmaceutical PreparationsIBA
12/2019 - 04/2008
13DNA (Deoxyribonucleic Acid)IBA
01/2021 - 04/2002
13Alanine Transaminase (SGPT)IBA
12/2020 - 12/2004
12Lamivudine (Epivir)FDA Link
02/2009 - 04/2002
11Hepatitis B Surface Antigens (HBsAg)FDA Link
01/2022 - 11/2008
11velpatasvirIBA
01/2021 - 12/2015
11daclatasvirIBA
01/2018 - 10/2014
11N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA
01/2016 - 04/2007
10MicroRNAs (MicroRNA)IBA
10/2020 - 05/2012
10SimeprevirIBA
01/2019 - 06/2012
9BilirubinIBA
11/2021 - 12/2009
9SphingolipidsIBA
03/2020 - 07/2014
9faldaprevirIBA
08/2016 - 12/2011
9NucleosidesIBA
08/2016 - 08/2007
8Anti-Bacterial Agents (Antibiotics)IBA
08/2022 - 09/2011
8grazoprevirIBA
01/2022 - 07/2015
8Sorafenib (BAY 43-9006)FDA Link
04/2021 - 07/2008
8ledipasvirIBA
11/2018 - 05/2014
8Vitamin DFDA LinkGeneric
10/2018 - 05/2011
8EnzymesIBA
01/2018 - 11/2004
8sofosbuvir drug combination ledipasvirIBA
01/2018 - 05/2014
8Interferon alpha-2 (Roferon-A)FDA Link
09/2012 - 12/2002
7glecaprevir and pibrentasvirIBA
01/2022 - 10/2017
7elbasvirIBA
01/2022 - 07/2015
7AlbuminsIBA
11/2021 - 12/2007
7Peptide Hydrolases (Proteases)FDA Link
10/2020 - 10/2006
7CholesterolIBA
07/2018 - 04/2006
7hydroxide ionIBA
01/2018 - 06/2009
7deleobuvirIBA
08/2016 - 12/2011
7TelbivudineFDA Link
01/2016 - 12/2007
6CytokinesIBA
01/2021 - 01/2005
6LipidsIBA
08/2020 - 04/2006
6Ritonavir (Norvir)FDA Link
11/2019 - 01/2014
6Tenofovir (Viread)FDA Link
02/2019 - 01/2013
6C-Reactive ProteinIBA
01/2018 - 05/2013
6NucleotidesIBA
01/2017 - 08/2007
6Indicators and Reagents (Reagents)IBA
10/2016 - 11/2004
6Amantadine (Aman)FDA LinkGeneric
01/2013 - 06/2003
5paritaprevirIBA
11/2019 - 01/2014
5Triglycerides (Triacylglycerol)IBA
07/2018 - 07/2003
5ombitasvirIBA
01/2018 - 01/2014
5adefovirIBA
12/2015 - 08/2005
5peginterferon alfa-2b (Pegintron)FDA Link
11/2011 - 06/2004
5adefovir dipivoxil (Hepsera)FDA Link
09/2011 - 12/2003
4Serum AlbuminIBA
07/2022 - 06/2008
4Messenger RNA (mRNA)IBA
09/2021 - 04/2004

Therapy/Procedure

203Therapeutics
08/2022 - 04/2002
35Liver Transplantation
08/2022 - 06/2003
10Drug Therapy (Chemotherapy)
04/2022 - 01/2011
10Aftercare (After-Treatment)
05/2018 - 08/2007
9Stents
06/2022 - 01/2014
9Duration of Therapy
01/2017 - 03/2004
6Retreatment
01/2021 - 03/2011
5Transplantation
08/2022 - 02/2007
5Drug Tapering
06/2015 - 02/2009
4Transjugular Intrahepatic Portasystemic Shunt
10/2022 - 05/2013
4Antibiotic Prophylaxis
01/2022 - 01/2020